Please try another search
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, and diagnostic companies. The company has a collaboration partnership with Celonic AG. The company was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Simon Gordon Douglas | 62 | 2011 | Non-Executive Chairman |
Adrian Robert Kinkaid | 56 | 2022 | CEO & Director |
Richard John Buick | 47 | 2011 | Chief Scientific Officer & Director |
Stephen Barry Smyth | 48 | 2023 | Company Secretary, Interim CFO & Director |
Colin J. Walsh | 68 | 2007 | Non-Executive Director |
Terence H. Rabbitts | - | 2022 | Member of Scientific Advisory Panel |
Matthew Paul Baker | 52 | 2022 | Member of Scientific Advisory Panel & Independent Non-Executive Director |
Charlotte Deane | - | 2022 | Member of Scientific Advisory Panel |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review